Boosting Checkpoint Immunotherapy with Biomaterials

Authors:
Publisher website
Google Scholar
Abstract
The immune checkpoint blockade (ICB) therapy has revolutionized the field of cancer treatment, while low response rates and systemic toxicity limit its clinical outcomes. With the rapid advances in nanotechnology and materials science, various types of biomaterials have been developed to maximize therapeutic efficacy while minimizing side effects by increasing tumor antigenicity, reversing immunosuppressive microenvironment, amplifying antitumor immune response, and reducing extratumoral distribution of checkpoint inhibitors as well as enhancing their retention within target sites. In this review, we reviewed current design strategies for different types of biomaterials to augment ICB therapy effectively and then discussed present representative biomaterial-assisted immune modulation and targeted delivery of checkpoint inhibitors to boost ICB therapy. Current challenges and future development prospects for expanding the ICB with biomaterials were also summarized. We anticipate this review will be helpful for developing emerging biomaterials for ICB therapy and promoting the clinical application of ICB therapy.
Funding Information
  • National Medical Research Council (CG21APR1005)
  • Science, Technology and Innovation Commission of Shenzhen Municipality (JSGG20220606141002004)
  • National University of Singapore (NUHSRO/2020/133/Startup/08, NUHSRO/2021/034/TRP/09/Nanomedicine)
  • National Natural Science Foundation of China (82222035)
  • Guangdong Basic and Applied Basic Research Foundation (2021A1515111036)

This publication has 287 references indexed in Scilit: